A Validated LC–MS/MS Assay for the Simultaneous Quantification of the FDA-Approved Anticancer Mixture (Encorafenib and Binimetinib): Metabolic Stability Estimation

The concurrent use of oral encorafenib (Braftovi, ENF) and binimetinib (Mektovi, BNB) is a combination anticancer therapy approved by the United States Food and Drug Administration (USFDA) for patients with BRAFV600E/V600K mutations suffering from metastatic or unresectable melanoma. Metabolism is c...

Descripción completa

Detalles Bibliográficos
Autores principales: Attwa, Mohamed W., Darwish, Hany W., Al-Shakliah, Nasser S., Kadi, Adnan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125647/
https://www.ncbi.nlm.nih.gov/pubmed/34063139
http://dx.doi.org/10.3390/molecules26092717

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125647/
https://www.ncbi.nlm.nih.gov/pubmed/34063139
http://dx.doi.org/10.3390/molecules26092717

Ejemplares similares